News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ILEX Oncology (ILXO) Reports Q3 2004 Results; Clofarabine FDA Panel Hearing Set For December


10/19/2005 5:11:52 PM

ILEX(TM) Oncology Inc. (Nasdaq:ILXO) today reported that global net sales of CAMPATH(R)/MABCAMPATH(R) (alemtuzumab) recorded by Schering AG, Germany (NYSE:SHR) (FSE:SCH) and its U.S. affiliate Berlex Laboratories Inc. totaled $18.2 million during the third quarter of 2004. That compares to sales of $16.1 million for the same quarter a year ago, a 13% increase. For the first nine months of 2004, global net sales of CAMPATH totaled $56.5 million, up 6% from $53.3 million in the first nine months of 2003.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES